Hyperuricemia

• 

  Subject Areas on Research

  • CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 
  • Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. 
  • Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. 
  • Dietary and commercialized fructose: Sweet or sour? 
  • Editorial Commentary: Prevention and treatment of atrial fibrillation: Is hyperuricemia the next target? 
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. 
  • Febuxostat: a new agent for lowering serum urate. 
  • Genetics of hyperuricemia and gout: implications for the present and future. 
  • Gout and its comorbidities. 
  • Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. 
  • Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? 
  • Hyperuricemia, gout, and cardiovascular disease--an important "muddle". 
  • Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. 
  • Normal glycine-C14-incorporation into uric acid in primary gout. 
  • On the mechanism of overproduction of uric acid in patients with primary gout. 
  • Overproduction of uric acid as the cause of hyperuricemia in primary gout. 
  • Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients. 
  • Progress in the pharmacotherapy of gout. 
  • Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. 
  • Safety of urate-lowering therapies: managing the risks to gain the benefits. 
  • Serum uric acid and hyperuricemia in U.S. adolescents: 40-year trends. 
  • The current state of care in gout: Addressing the need for better understanding of an ancient disease. 
  • Update on the management of hyperuricemia and gout. 
  • Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. 
  • Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Distinguished Professor of Cardiology, Medicine, Clinical Pharmacology